FAQs

The information herein is intended to assist practitioners in providing appropriate care for patients when using radiopharmaceuticals. This information is not intended to establish, nor should it be used to establish, a legal standard of care. It is important to adhere to all applicable standards when handling and administering radiopharmaceuticals. Institutions are responsible for ensuring their compliance with all laws and regulations by establishing their own policies, procedures, and guidance. Novartis Pharmaceuticals Corporation does not endorse or recommend any specific course of action, or any third-party organization referenced herein.

References: 1. Mittra ES, Wong RKS, Winters C, et al.Cancer Med. 2024;13(3):e6780. doi:10.1002/cam4.6780 2. US Nuclear Regulatory Commission (NRC). Section 2.101 Filing of Application. Updated January 3, 2024. Accessed January 3, 2025. www.nrc.gov/reading-rm/doc-collections/cfr/part002/part002-0101.html 3. Cappon DJ, Fang S, Berry K, et al. Health Phys. 2023;124(2):139-146. doi:10.1097/hp.0000000000001644 4. Calais J, Eulau SM, Gardner L, et al. Cancer Treat Rev. 2023;115:102524. doi:10.1016/j.ctrv.2023.102524 5. Herrmann K, Giovanella L, Santos A, et al. Eur J Nucl Med Mol Imaging. 2022;49(7):2300-2309. doi:10.1007/s00259-022-05785-x 6. Mittra ES, Wong RKS, Winters C, et al. Cancer Med. 2024;13(3)(suppl):e6780. doi:10.1002/cam4.6780 7. Data on file. Expert Working Group Experience. Novartis Pharmaceuticals Corp; 2025. 8. US Nuclear Regulatory Committee (NRC). Technical Assistance Request, National Institutes of Health, Bethesda, Maryland, Regarding Exemption from 10 CFR 35.315 (a) (7). Updated October 31, 2017. Accessed December 31, 2024. www.nrc.gov/about-nrc/radiation/protects-you/hppos/hppos316.html 9. US Nuclear Regulatory Commission (NRC). Section 20.1904 Labeling Containers. Updated March 24, 2021. Accessed January 2, 2025. www.nrc.gov/reading-rm/doc-collections/cfr/part020/part020-1904.html 10. Lutathera. Prescribing information. Novartis Pharmaceuticals Corp. 11. Pluvicto. Prescribing information. Novartis Pharmaceuticals Corp.